Congratulations to our colleagues from DEBN for a lecture at European Association of Urology Congress 23.
EAU 23, the largest European urology congress was held on March 11 in Milan.
Marcin Sieczkowski, MD, FEBU and Artur Gibas, MD, PhD, FEBU presented their innovative solution Drug-Eluting Biopsy Needle (DEBN). DEBN presents a new transrectal prostate biopsy approach which may improve tolerability and safety.
DEBN is a patented (PCT/PL2016/000006) medical device which is a novel approach to the problem of transrectal ultrasound prostate biopsy (TRUS-Bx) related infectious complications. It consists of a polymer coated biopsy needle and anaesthesia needle containing an antibiotic that is released directly to the prostate during the biopsy procedure. This solution may allow the co-administration of various antibiotics, thereby broadening their spectrum of activity and potentially reducing the number of infectious complications. DEBN is the first medical device to enable simultaneous organ-targeted delivery of antibiotics during prostate biopsy procedure. The presented model of DEBN contains poly(vinyl alcohol) and amikacin sulphate.
As Orphinic Scientific, we are proud of the successes of our portfolio company. We systematically support new innovative biopharma projects that can improve the quality of life - said Adam Kruszewski, CEO of Orphinic Scientific SA
